Keywords:
Lung, Oncology, PET-CT, Radiation therapy / Oncology, Cancer, Outcomes
Authors:
N. Lee1, J. Shafiq1, M. Field1, C. Fiddler2, S. Varadarajan3, S. Gandhidasan2, E. Hau3, S. Vinod1; 1Sydney, NSW/AU, 2Wollongong, NSW/AU, 3Blacktown, NSW/AU
DOI:
10.26044/ranzcr2021/R-0268
Purpose
Over the last two decades, while there has been an increase in the use of curative treatment for non-small cell lung cancer (NSCLC), significant patterns of radiotherapy underutilisation persist across Australia and internationally [1,2]. One strategy for addressing such variation is the development of a survival prediction model that integrates individual, medical and environmental factors unaccounted for by guidelines that commonly influence treatment decisions. This would have the potential to objectively evaluate treatment benefits in individual patients to facilitate shared decision-making, tailor patient management and optimise outcomes [3]. There are currently limited data on survival prediction models in contemporary inoperable NSCLC patients [4]. The objective of this study was to develop and validate survival prediction models in a cohort of inoperable stage I-III NSCLC patients and in a cohort treated with radiotherapy.